Aclaris Therapeutics (ACRS) Other Non-Current Liabilities (2016 - 2026)

Aclaris Therapeutics' Other Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 67.13% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.4 million (down 67.13% YoY), while the FY2025 annual figure was $11.0 million, up 147.8% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $1.4 million, down from $11.0 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $33.1 million in Q4 2022, with the low at $1.4 million in Q1 2026.
• The 5-year median for Other Non-Current Liabilities is $9.2 million (2024), against an average of $13.6 million.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities soared 794.44% in 2022, then slumped 92.95% in 2023.
• Aclaris Therapeutics' Other Non-Current Liabilities stood at $33.1 million in 2022, then slumped by 90.71% to $3.1 million in 2023, then surged by 44.4% to $4.4 million in 2024, then surged by 147.8% to $11.0 million in 2025, then sank by 87.13% to $1.4 million in 2026.
• Business Quant data shows ACRS's Other Non-Current Liabilities at $1.4 million in Q1 2026, $11.0 million in Q4 2025, and $1.7 million in Q3 2025.